Latest revenue
$204.6M
as of 2026-03-31
Latest net income
$-11.3M
as of 2026-03-31
Net margin
-5.5%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $1.26B
- Enterprise value
- $1.26B
- P/E (trailing)
- 8.7×
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $147.66
- 52-wk low
- $39.61
- Beta
- —
- Shares out
- 28.8M
5-year trend
What this company does
Item 1. Business. Overview We are a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea ("OSA"). Our proprietary Inspire system is the first FDA, European Union ("EU") Regulation No. 2017/745 ("MDR" or "EU Medical Devices Regulation"), and Japan Pharmaceuticals and Medical Devices Agency-approved neurostimulation technology of its kind that provides a safe and effective treatment for patients with moderate to severe OSA. We have developed a novel, closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open…
AI summary unavailable — showing raw filing excerpt
Generated from INSP's filing dated 2026-02-13
Key risks
Item 1A. Risk Factors. Investing in our common stock involves a high degree of risk. These risks include, but are not limited to, those described below, each of which may be relevant to an investment decision. You should carefully consider the risks described below, together with the other information included or incorporated by reference in this Annual Report on Form 10-K. The realization of any of the following risks could have a significant adverse effect on our reputation, business, financial condition, results of operations, growth, and our ability to accomplish our strategic objectives. In that event, the trading price of our common stock could decline. Other events that we do not…
AI summary unavailable — showing raw filing excerpt
Generated from INSP's filing dated 2026-02-13
Profitability
Gross margin
85.4%
0.8%Operating margin
5.6%
24.3%Net margin
15.9%
139.2%Return on equity
21.1%
171.8%Return on assets
16.0%
142.1%Leverage
Debt / equity
0.32×
83.4%Long-term debt / equity
0.00×
100.0%Debt / assets
24.0%
63.4%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $204.6M | +1.6% | $-11.3M | -477.5% | -5.5% |
Q4 2025 2025-12-31 | $269.1M | +12.2% | $133.7M | +194.2% | 49.7% |
Q3 2025 2025-09-30 | $224.5M | +10.5% | $9.3M | -49.0% | 4.2% |
Q2 2025 2025-06-30 | $217.1M | +10.8% | $-600.0K | -183.0% | -0.3% |
Q1 2025 2025-03-31 | $201.3M | +22.7% | $3.0M | +129.9% | 1.5% |
Q4 2024 2024-12-31 | $239.7M | — | $45.4M | — | 19.0% |
Q3 2024 2024-09-30 | $203.2M | +32.5% | $18.3M | +314.1% | 9.0% |
Q2 2024 2024-06-30 | $195.9M | +29.6% | $-212.0K | +98.2% | -0.1% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Surgical & Medical Instruments & Apparatus · SIC 3841
Your notes
Keep private notes on INSP — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$1.6M
Net activity
−$1.6M
Distinct insiders
4
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns INSP
Institutional value
$782.0M
Total shares held
15.7M
Distinct holders
170
-172 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 3.5M | $183.1M | -1.3K (-0.0%) | Trimmed |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.6M | $84.4M | — | New |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 1.3M | $65.3M | — | New |
| 4 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 1.1M | $58.7M | -23.9K (-2.1%) | Trimmed |
| 5 | Artisan Partners Limited Partnership | 780.6K | $40.3M | -5.2K (-0.7%) | Trimmed |
| 6 | Walleye Capital LLC | 717.0K | $37.0M | +638.8K (+816.7%) | Added |
| 7 | UBS Group AG | 638.9K | $33.0M | +227.6K (+55.3%) | Added |
| 8 | Assenagon Asset Management S.A. | 520.2K | $26.8M | +255.2K (+96.3%) | Added |
| 9 | DEUTSCHE BANK AG\ | 513.2K | $26.5M | -3.6K (-0.7%) | Trimmed |
| 10 | abrdn plc | 477.5K | $24.6M | +16.6K (+3.6%) | Added |
| 11 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 448.8K | $23.1M | -14.5K (-3.1%) | Trimmed |
| 12 | BNP PARIBAS FINANCIAL MARKETS | 319.8K | $16.5M | -135.1K (-29.7%) | Trimmed |
| 13 | Jefferies Financial Group Inc. | 306.4K | $15.8M | -1.2K (-0.4%) | Trimmed |
| 14 | DIMENSIONAL FUND ADVISORS LP | 234.7K | $12.1M | -106.7K (-31.3%) | Trimmed |
| 15 | VANGUARD FIDUCIARY TRUST CO | 167.7K | $8.6M | — | New |
| 16 | Champlain Investment Partners, LLC | 159.0K | $8.2M | -44.1K (-21.7%) | Trimmed |
| 17 | Y-Intercept (Hong Kong) Ltd | 158.3K | $8.2M | +87.6K (+124.1%) | Added |
| 18 | Bank of New York Mellon Corp | 148.8K | $7.7M | -67.0K (-31.1%) | Trimmed |
| 19 | WASATCH ADVISORS LP | 138.6K | $7.1M | +22.5K (+19.4%) | Added |
| 20 | LOS ANGELES CAPITAL MANAGEMENT LLC | 133.0K | $6.9M | +132.8K (+94193.6%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once INSP's latest filing finishes processing.